Chewy Is Down 23% in 2026. Is This a Once-in-a-Lifetime Buying Opportunity?

Chewy shares are down ~23% YTD and have underperformed the S&P 500 by about 22 percentage points. Operationally revenue grew 8.3% with active customers up 4.9% to 21.2M, sales per active customer +4.9% to $595, and recurring delivery revenue +13.6% to $2.6B. Valuation remains rich at a P/E of 52 (vs. S&P 29 and 68 at end-2025), leading the author to view the stock as expensive and not a buy despite steady revenue gains.

Analysis

Market pricing implies Chewy must execute a multi-year transition from a pure e-commerce retailer to a vertically integrated services business without disturbing unit economics. The vet-clinic rollout is the key inflection: if clinics scale to meaningful contribution (low-single-digit revenue share within 12–24 months) they could lift average revenue per active customer by converting discretionary purchases into higher-margin recurring services, but the initiative also introduces fixed-cost leverage risk and licensing/regulatory exposures that can depress near-term free cash flow.

Second-order winners from a Chewy stumble are incumbent physical service providers (Petco/WOOF) and omnichannel grocers that can bundle pet care with in-store foot traffic — these operators can monetize visit frequency immediately while avoiding the capex and fulfillment complexity Chewy faces. On the supply side, concentrated pet-food manufacturing and commodity protein/ingredient cycles mean COGS volatility could swing gross margin +/-200–400bps at the category level over a year, amplifying any revenue miss into headline EPS misses.

Technically, the stock appears priced for a flawless execution path; that makes short-term catalysts binary — quarterly active-customer growth and margin progression over the next 2–3 earnings seasons are likely to drive outsized moves. For investors comfortable with event risk, the asymmetric payoff is skewed to the downside unless Chewy demonstrably converts clinic unit economics into stable contribution and reduces fulfillment costs per order by at least 5–7% within 12 months.

Key Decisions for Investors

• Short CHWY equity (target size 2–4% NAV) with a 6–12 month horizon — entry on any pop above prior resistance or after next quarter if active-customer growth decelerates to <3% YoY; target downside 30–50%, stop-loss at +20% to limit tail gamma risk.
• Pair trade: Short CHWY / Long WOOF (1:1 dollar exposure) over 9–18 months — rationale: rotate exposure from execution-dependent digital retail to service-heavy operator; expected asymmetric payoff: WOOF +30–50% if Chewy execution falters while CHWY falls 30%+, netting substantial spread capture.
• Buy CHWY 9–12 month put spreads to cap premium cost (e.g., buy Sep-2026 puts, sell lower strike) sized 1–2% NAV — objective to capture a >25% move down with defined max loss; reduce position if implied volatility jumps >25% on event risk.
• Event-driven call spread long on CHWY (3–6 month) as a contrarian hedge: if management reports clinic economics break even and gross margins improve >200bps, a tight call spread (buy low-strike, sell ~20% higher strike) offers 2–3x upside with limited capital at risk.